AbbVie (NYSE:ABBV) Trading Up 3% – Time to Buy?

Shares of AbbVie Inc. (NYSE:ABBV) were up 3% during trading on Thursday . The stock traded as high as $229.05 and last traded at $227.5660. Approximately 8,689,308 shares traded hands during trading, an increase of 14% from the average daily volume of 7,633,555 shares. The stock had previously closed at $220.89.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 results and guidance beat expectations with record net sales and continued strength in immunology brands (Skyrizi, Rinvoq); management raised FY guidance, supporting outlook for durable cash flow and dividends. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: AbbVie completed a post?marketing study for Rinvoq in Korea, adding real?world data that supports label adoption and continued immunology growth — a commercial tailwind for Rinvoq uptake. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Positive Sentiment: Sell?side support: Cantor Fitzgerald and other bulls reiterated favorable ratings/price targets after the quarter, reinforcing investor confidence in growth and dividend stability. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Neutral Sentiment: Analyst coverage and reports (Argus and others) are reframing valuation assumptions — useful for investors but mix of views leaves near?term direction dependent on execution. Analyst Report: AbbVie Inc
• Neutral Sentiment: Clinical pipeline updates (e.g., Phase 2 elezanumab in acute cervical spinal cord injury) are being monitored; progress could be meaningful long term but currently remains binary/uncertain. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Negative Sentiment: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — legal fight highlights risk to Botox pricing and potential revenue pressure if the selection stands. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure: J&J’s heavy TV ad spend for Tremfya could slow market share gains for Rinvoq and Skyrizi in certain dermatology/psoriasis segments. J&J’s Tremfya roars 2026 with massive TV ad spend, trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: Operational/pricing headwinds: reporting on Medicaid concessions and reshaped U.S. operations signals potential margin pressure in the near term even as company focuses on growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ABBV shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research note on Tuesday, November 4th. Finally, Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Stock Performance

The stock has a market capitalization of $402.20 billion, a P/E ratio of 96.43, a PEG ratio of 0.77 and a beta of 0.35. The firm has a fifty day moving average price of $223.45 and a two-hundred day moving average price of $220.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 earnings per share. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ABBV. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter valued at about $26,000. Chelsea Counsel Co. bought a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie in the second quarter worth approximately $28,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter valued at $28,000. Finally, Westend Capital Management LLC purchased a new position in shares of AbbVie during the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.